Cargando…
Mitigating Deficiencies in Evidence during Regulatory Assessments of Advanced Therapies: A Comparative Study with Other Biologicals
Advanced therapy medicinal products (ATMPs) comprising cell therapy, gene therapy, and tissue-engineered products, offer a multitude of novel therapeutic approaches to a wide range of severe and debilitating diseases. To date, several advanced therapies have received marketing authorization for a va...
Autores principales: | Elsallab, Magdi, Bravery, Christopher A., Kurtz, Andreas, Abou-El-Enein, Mohamed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327881/ https://www.ncbi.nlm.nih.gov/pubmed/32637456 http://dx.doi.org/10.1016/j.omtm.2020.05.035 |
Ejemplares similares
-
Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell‐Based Interventions
por: Bauer, Gerhard, et al.
Publicado: (2018) -
Long-term response to autologous anti-CD19 chimeric antigen receptor T cells in relapsed or refractory B cell acute lymphoblastic leukemia: a systematic review and meta-analysis
por: Elsallab, Magdi, et al.
Publicado: (2023) -
Cell and Gene Therapy Trials: Are We Facing an ‘Evidence Crisis’?
por: Abou-El-Enein, Mohamed, et al.
Publicado: (2019) -
CAR NK-92 cell–mediated depletion of residual TCR(+) cells for ultrapure allogeneic TCR-deleted CAR T-cell products
por: Kath, Jonas, et al.
Publicado: (2023) -
Accelerating Patients’ Access to Advanced Therapies in the EU
por: Elsanhoury, Ahmed, et al.
Publicado: (2017)